A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
| Autor: | Potchavit Aphinives, Dhanes Rangsrikajee, Ongart Somintara, Chaiyut Thanapaisal, Damnern Vachirodom |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Gynecology
medicine.medical_specialty Aromatase inhibitor tamoxifen medicine.drug_class business.industry Letrozole estrogen receptor-positive hormonal responsive Anastrozole Targets and Therapy [Breast Cancer] Mean age medicine.disease Breast cancer Oncology Internal medicine medicine Overall survival Stage (cooking) business Tamoxifen medicine.drug Original Research |
| Zdroj: | Breast Cancer : Targets and Therapy |
| ISSN: | 1179-1314 |
| Popis: | Potchavit Aphinives, Damnern Vachirodom, Chaiyut Thanapaisal, Dhanes Rangsrikajee, Ongart SomintaraDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandBackground: We previously studied the noninferiority of anastrozole (ANZ) versus ANZ followed by letrozole (A-LTZ) due to reimbursement policy. We found that patients with A-LTZ had better overall survival (OS) than did patients with ANZ alone. This study aimed to prove that patients with A-LTZ also had better OS than patients with letrozole (LTZ) alone.Methods: All medical records of the breast cancer patients taking LTZ with or without ANZ between 2004 and 2013 were reviewed. All patients were divided into two groups: the LTZ group included patients treated with LTZ alone, and the A-LTZ group included patients treated with ANZ who were automatically changed to LTZ due to change of the reimbursement policy.Results: From 359 cases, there were 179 cases in the LTZ group and 180 cases in the A-LTZ group. The mean age of patients in the LTZ group was 53.7 years and in the A-LTZ group was 54.2 years. The distribution of clinical stages among the LTZ group versus the A-LTZ group was 21 versus 4 (stage 1), 86 versus 116 (stage 2), 55 versus 46 (stage 3), and 17 versus 14 (stage 4), respectively. Among the LTZ patients, 63.7% took aromatase inhibitor monotherapy and 36.3% had a switching strategy, while in the A-LTZ group, 53.9% took AI monotherapy and 46.1% had a switching strategy. OS of the A-LTZ group was longer than that of the LTZ group.Conclusion: The patients in A-LTZ, taking ANZ followed by LTZ had better OS than those in LTZ, taking LTZ alone.Keywords: estrogen receptor-positive, hormonal responsive, tamoxifen |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|